Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy

Lung Cancer

Volumn 44, Issue 2, 2004, Pages 213-220

  Wirth, Lori J ^a,b,c   Carter, Mark R ^d   Jänne, Pasi A ^a,b,c   Johnson, Bruce E ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Carcinoid tumor; Chemotherapy; Lung neoplasms; Neuroendocrine carcinoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINCRISTINE;

ADULT; AGED; ALLERGY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; LUNG CARCINOMA; MALE; MEDICAL RECORD; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PULMONARY CARCINOID; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1842785855     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.11.016     Document Type: Article

References (36)

1. Salgia R., Skarin A., Yang F.-C., Goldstein M., Harpole D. Carciniod tumors of the lung. Contemp. Surg. 51:1997;135-144.
2. Kulke M.H., Mayer R.J. Carcinoid tumors. N. Engl. J. Med. 340(11):1999;858-868.
3. Travis W.D., Rush W., Flieder D.B., Falk R., Fleming M.V., Gal A.A.et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 22:1998;934-944.
4. Garcia-Yuste M., Matilla J., Alvarez-Gago T., Duque J., Heras F., Cerezal L.et al. Prognostic factors in neuroendocrine lung tumors: A Spanish multicenter study. Ann. Thorac. Surg. 70:2000;258-263.
5. Fink G., Krelbaum T., Yellin A., Bendayan D., Saute M., Glazer M.et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 119:2001;1647-1651.
6. Filosso P.L., Rena O., Doanti G., Casadio C., Ruffini E., Papalia E.et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J. Thorac. Cardiovasc. Surg. 123:2002;303-309.
7. Janne P.A., Freidlin B., Sacman S., Johnson B.E. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 95:2002;1528-1538.
8. Chute J.P., Chen T., Fiegal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol. 17:1999;1794-1801.
9. Iyoda A., Hiroshima K., Baba M., Saitoh Y., Ohwada H., Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann. Thorac. Surg. 73:2002;1049-1054.
10. Dresler C.M., Ritter J.H., Patterson G.A., Ross E., Bailey M.S., Wick M.R. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann. Thorac Surg. 63:1997;180-185.
11. Kaplan B., Stevens C.W., Allen P., Liao Z., Komaki R. Outcomes and patterns of failure in bronchial carcinoid tumors. Int. J. Radiat. Oncol. Biol. Phys. 55:2003;125-131.
12. Thomas C.F., Tazelaar H.D., Jett J.R. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph nodes involvement. Chest. 119:2001;1143-1150.
13. Response evaluation criteria in solid tumors (RECIST) quick reference. http://www.nci.nih.gov/bip/RECIST.htm.
14. Kaplan E.L., Meier P. Nonparametric estimation for incomplete observation. J. Am. Stat. Assoc. 53:1958;457-481.
15. Moertel C.G., Hanley J.A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials. 2:1979;327-334.
16. Engstrom P.F., Lavin P.T., Moertel C.G., Folsch E., Douglass H.O. Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 2:1984;1255-1259.
17. Granberg D., Eriksson B., Wilander E., Grimfjard P., Fjallskog M.L., Oberg K.et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann. Oncol. 2:2001;1383-1391.
18. Harpole D.H., Feldman J.M., Buchanan S., Young W.G., Wolfe W.G. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann. Thorac. Surg. 54:1992;50-55.
19. Martini N., Zaman M.B., Bains M.S., Burt M.E., McCormack P.M., Rusch V.W.et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J. Thorac. Cardiovasc. Surg. 107:1994;1-6. discussion 6-7.
20. Valli M., Fabris G.A., Dewar A., Hornall D., Sheppard M.N. Atypical carcinoid tumor of the lung: a study of 33 cases with prognostic features. Histopathology. 24:1994;363-369.
21. Beasley M.B., Thunnissen F., Branbilla E., Haselton P., Steele R., Hammar S.P.et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum. Pathol. 31(10):2000;1255-1265.
22. Cooper W.A., Thourani V.H., Gal A.A., Lee R.B., Mansour K.A., Miller J.I. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest. 119:2001;14-18.
23. Bukowski R.M., Johnson K.G., Peterson R.F., Stephens R.L., Rivkin S.E., Neilan B.et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer. 60:1987;2891-2895.
24. Ansell S.M., Pitot H.C., Burch P.A., Kvols L.K., Mahoney M.R., Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 91:2001;1543-1548.
25. Johnson B.E. Management of small cell lung cancer. Clin. Chest. Med. 23:2002;225-239.
26. Evans W.K., Feld R., Murray N., Willan A., Coy P., Osoba D.et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann. Intern. Med. 107:1987;451-458.
27. Ihde D.C., Mulshine J.L., Kramer B.S., Steinberg S.M., Linnoila R.I., Gazdar A.F.et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12:1994;2022-2034.
28. Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C.et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 11:1993;336-344.
29. Bunn P.A., Crowley J., Kelly K., Hazuka M.B., Beasley K., Upchurch C.et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J. Clin. Oncol. 13:1995;1632-1641.
30. Miller A.A., Herndon J.E. 2nd, Hollis D.R., Ellerton J., Langleben A., Richards F. 2ndet al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J. Clin. Oncol. 13:1995;1871-1879.
31. Turrisi A.T. 3rd, Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R.et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340:1999;265-271.
32. Murray N., Livingston R.B., Shepherd F., James K., Zee B., Langleben A.et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J. Clin. Oncol. 17:1999;2300-2308.
33. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A.et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:2002;85-91.
34. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U.S.A. 98:2001;13790-13795.
35. Anbazhagan R., Tihan T., Bornman D.M., Johnston J.C., Saltz J.H., Weigering A.et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 59:1999;5119-5122.
36. Ullmann R., Petzmann S., Klemen H., Fraire A.E., Haselton P., Popper H.H. The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues. Genes Chromosomes Cancer. 34:2002;78-85.